ENDRA Life Sciences enters first amendment to merger agreement on October 1, 2026
NDRA•ENDRA Life Sciences entered a first amendment to its merger agreement on October 1, 2026; its filing also said Renergen’s borrowing capacity from ASPI increased to $120 million and is to increase to $200 million.
1. Merger amendment and borrowing
ENDRA Life Sciences entered a first amendment to its merger agreement on October 1, 2026. The filing said Renergen’s borrowing capacity from ASPI increased to $120 million and is to be increased to $200 million.
